Maxim analyst Jason McCarthy upgraded Moleculin Biotech (MBRX) to Buy from Hold with a $4 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Advances Clinical Trials Amid Financial Losses
- Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target
- Moleculin Biotech Shares Corporate Presentation Update
- Moleculin Biotech reports FY24 EPS ($6.32) vs. (15.07) last year
- MBRX Upcoming Earnings Report: What to Expect?